Quest Diagnostics Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Quest Diagnostics Inc trades at $231.5 (market cap $25.48B), while iShares 7-10 Year Treasury Bond ETF trades at $89.36 (market cap $41.13B). The key difference: iShares 7-10 Year Treasury Bond ETF is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| DGX | IEF | |
|---|---|---|
Market Cap | $25.48B | $41.13B |
Volume | 941,866 | 10,340,382 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $97.99 |
52-Week Low | $173.49 | $88.92 |
Typical Hold Time | 56 Days | 108 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
IEF is trading at $89.11, down 0.02% with a bearish technical outlook. The fund shows neutral oscillators but bearish moving averages, with RSI levels below 30 indicating potential oversold conditions. Recent dividend payments of $0.31-$0.33 provide income support amid market volatility. The bond market faces pressure from rising Treasury yields and inflation concerns.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current yields offer attractive entry points for income investors, persistent inflation and Fed policy uncertainty pose significant risks. Defensive positioning in fixed income suggests limited near-term upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →